2. Academic Validation
  3. Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

  • J Med Chem. 2020 Dec 10;63(23):14740-14760. doi: 10.1021/acs.jmedchem.0c01296.
Li-Qiang Sun 1,  Eric Mull 2,  Stanley D'Andrea 2,  Barbara Zheng 1,  Sheldon Hiebert 2,  Eric Gillis 2,  Michael Bowsher 2,  Sarkunam Kandhasamy 3,  Venkata Rao Baratam 3,  Sunitha Puttaswamy 3,  Nagalakshmi Pulicharla 3,  Sureshbabu Vishwakrishnan 3,  Subba Reddy 3,  Ravi Trivedi 3,  Sarmistha Sinha 3,  Sankar Sivaprasad 3,  Abhijith Rao 3,  Salil Desai 3,  Kaushik Ghosh 3,  Rushith Anumula 3,  Amit Kumar 3,  Ramkumar Rajamani 4,  Ying-Kai Wang 1,  Hua Fang 2,  Arvind Mathur 2,  Richard Rampulla 2,  Tatyana A Zvyaga 2,  Kathy Mosure 4,  Susan Jenkins 2,  Paul Falk 2,  Debarati M Tagore 3,  Chaoqun Chen 2,  Kishore Rendunchintala 3,  James Loy 4,  Nicholas A Meanwell 1,  Fiona McPhee 4,  Paul M Scola 4
Affiliations

Affiliations

  • 1 Bristol Myers Squibb Research and Early Development, Route 206 & Province Line Road, Princeton, New Jersey 08543, United States.
  • 2 Bristol Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
  • 3 Biocon-Bristol Myers Squibb Research and Development Center, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India.
  • 4 Bristol Myers Squibb Research and Early Development, 100 Binney Street, Cambridge, Massachusetts 02142, United States.
PMID: 33226226 DOI: 10.1021/acs.jmedchem.0c01296
Abstract

The discovery of a pan-genotypic hepatitis C virus (HCV) NS3/4A protease inhibitor based on a P1-P3 macrocyclic tripeptide motif is described. The all-carbon tether linking the P1-P3 subsites of 21 is functionalized with alkyl substituents, which are shown to effectively modulate both potency and absorption, distribution, metabolism, and excretion (ADME) properties. The CF3Boc-group that caps the P3 amino moiety was discovered to be an essential contributor to metabolic stability, while positioning a methyl group at the C1 position of the P1' cyclopropyl ring enhanced plasma trough values following oral administration to rats. The C7-fluoro, C6-CD3O substitution pattern of the P2* isoquinoline heterocycle of 21 was essential to securing the targeted potency, pharmacokinetic (PK), and toxicological profiles. The C6-CD3O redirected metabolism away from a problematic pathway, thereby circumventing the time-dependent cytochrome P (CYP) 450 inhibition observed with the C6-CH3O prototype.

Figures